Candidal cheilitis
ICD-10 B37.83 is a billable code used to indicate a diagnosis of candidal cheilitis.
Candidal cheilitis, also known as angular cheilitis or perleche, is a fungal infection characterized by inflammation and cracking at the corners of the mouth. It is primarily caused by the overgrowth of Candida species, particularly Candida albicans, which is a normal inhabitant of the oral cavity but can proliferate under certain conditions. This condition is often seen in individuals with compromised immune systems, such as those with diabetes, HIV/AIDS, or those undergoing immunosuppressive therapy. Symptoms include redness, swelling, and painful fissures at the labial commissures, which can lead to secondary bacterial infections if left untreated. Diagnosis is typically clinical, supported by the presence of characteristic lesions and, in some cases, confirmed by culture. Treatment involves the use of topical antifungal agents, such as clotrimazole or miconazole, and addressing any underlying conditions that may predispose the patient to candidiasis. In immunocompromised patients, systemic antifungal therapy may be necessary to effectively manage the infection and prevent recurrence.
Detailed clinical notes on the appearance of lesions, treatment plans, and follow-up assessments.
Patients presenting with angular cheilitis, especially those with a history of skin conditions or immunosuppression.
Consideration of differential diagnoses such as herpes simplex or contact dermatitis.
Comprehensive history of immunocompromised conditions, treatment regimens, and response to therapy.
Patients with recurrent candidal infections requiring systemic antifungal therapy.
Assessment of potential drug interactions with antifungal medications.
Used when a patient presents for evaluation and management of candidal cheilitis.
Document the history, examination findings, and treatment plan.
Dermatologists may need to provide additional details on skin examination.
Common treatments include topical antifungal medications such as clotrimazole or miconazole. In more severe cases, systemic antifungal therapy may be required, especially in immunocompromised patients.
